A holistic approach to iron chelation therapy in transfusion-dependent thalassemia patients with serum ferritin below 500 μg/L
- 1 September 2020
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 95 (9), E230-E232
- https://doi.org/10.1002/ajh.25860
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studiesThe Lancet Child & Adolescent Health, 2018
- Renal safety under long‐course deferasirox therapy in iron overloaded transfusion‐dependent β‐thalassemia and other anemiasAmerican Journal of Hematology, 2018
- Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion‐dependent thalassaemiaEuropean Journal of Haematology, 2017
- Deferasirox effect on renal haemodynamic parameters in patients with transfusion‐dependent β thalassaemiaBritish Journal of Haematology, 2014
- Incidence of deferasirox‐associated renal tubular dysfunction in children and young adults with beta‐thalassaemiaBritish Journal of Haematology, 2014
- Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-upBlood, 2011
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009
- Effect of transfusional iron intake on response to chelation therapy in β-thalassemia majorBlood, 2008
- A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaBlood, 2006
- BIOCHEMISTRY OF OXYGEN TOXICITYAnnual Review of Biochemistry, 1989